Can you take Encorafenib with Little Tummys Laxative Drops?

The senna in Little Tummys Laxative Drops has a major potential interaction with Appendicitis.

The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis. These patients may be candidates for emergency surgery. Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.

The senna in Little Tummys Laxative Drops has a major potential interaction with Bleeding Disorder.

The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures. These preparations may cause irritation, burning sensation, and proctitis.

Encorafenib has a moderate potential interaction with Cardiomyopathy.

Cardiomyopathy, manifesting as left ventricular dysfunction, has been reported with use of encorafenib in combination with binimetinib. The safety of encorafenib has not been established in patients with baseline ejection fraction below 50% or below the institutional lower limit of normal. Patients with cardiovascular risk factors should be closely monitored during therapy with encorafenib. Assess ejection fraction at baseline, 1 month after initiation, and every 2 to 3 months during therapy. Withhold, reduce dose, or permanently discontinue therapy based on severity of adverse cardiovascular effects.

The senna in Little Tummys Laxative Drops has a major potential interaction with Gastrointestinal Obstruction.

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

Encorafenib has a moderate potential interaction with Heart Failure.

Encorafenib is associated with dose-dependent QTc interval prolongation in some patients. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during therapy with encorafenib. Withhold, reduce dose, or permanently discontinue for QTc > 500 ms.

Encorafenib has a moderate potential interaction with Hypokalemia.

Encorafenib is associated with dose-dependent QTc interval prolongation in some patients. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during therapy with encorafenib. Withhold, reduce dose, or permanently discontinue for QTc > 500 ms.

The senna in Little Tummys Laxative Drops has a major potential interaction with Inflammatory Bowel Disease.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

Encorafenib has a moderate potential interaction with Liver Disease.

A recommended dose of encorafenib has not been established for patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. Dose adjustment is not recommended in patients with mild hepatic impairment (Child-Pugh A).

Encorafenib has a moderate potential interaction with Long QT Syndrome.

Encorafenib is associated with dose-dependent QTc interval prolongation in some patients. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during therapy with encorafenib. Withhold, reduce dose, or permanently discontinue for QTc > 500 ms.

Encorafenib has a moderate potential interaction with Magnesium Imbalance.

Encorafenib is associated with dose-dependent QTc interval prolongation in some patients. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during therapy with encorafenib. Withhold, reduce dose, or permanently discontinue for QTc > 500 ms.

Encorafenib has a moderate potential interaction with Renal Dysfunction.

A recommended dose of encorafenib has not been established for patients with severe renal impairment (CrCl < 30 mL/min). Caution and monitoring is advised if used on these patients. No dose adjustment is recommended for patients with mild to moderate renal impairment (CrCl 30 to < 90 mL/min).

Encorafenib has a moderate potential interaction with Visual Defect/Disturbance.

Encorafenib, administered in combination with binimetinib, may cause uveitis, including iritis and iridocyclitis. Assess for visual symptoms at each visit and perform ophthalmologic evaluations at regular intervals, or as indicated, for new or worsening visual disturbances.